Zhejiang Orient Gene Biotech Co., Ltd, founded in December 2005, listed on SSE STAR MARKET on Feb. 5th, 2020. We specialize in R&D, production and sales of in vitro diagnostic products, and insist on the application of the cutting-edge "genetic engineering" technology to product development and industrial layout. Orient gene is accelerating the industrialization and marketing process of its three core platforms: POCT rapid diagnostics, molecular diagnostics and liquid biochips.
POCT rapid diagnostics is the current flagship product line of Orient Gene. We offer hundreds of POCT instant diagnostics assorted into five categories: Infectious Disease (including COVID-19 Test series), Drug of Abuse, Pregnancy and Fertility,Cardiac Marker and Tumor Marker.The products are exported to more than 100 countries and regions worldwide, with overseas sales accounting for about 95%. At present, Orient Gene has a complete industry chain covering from raw material, POCT diagnostics to rapid diagnostic instruments, and will focus on the industrial upgrading from "product provider" to "product provider and third-party testing".
Confronting the COVID-19 outbreak in 2020, orient gene has responded quickly to the demand for epidemic test and made efforts tosupport the fight against the epidemic. We have developed a series of COVID-19 testreagents which have been widely recognized by the market.Orient Gene has become one of the key exporters of COVID-19 test reagents in China, accounted for approximately 16% of the total export volume of the country.
| Full name | Zhejiang Orient Gene Biotech Co., Ltd |
|---|---|
| Abbreviations | Orient Biotech |
| Code | 688298 |
| Founded | 2005-12-01 |
| Listing | 2020-02-05 |
| Domicile | Anji, Zhejiang, China |
| zqb@orientgene.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Biomedicine Manufacturing(C27) |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 14.28 | 0.91 | 0.73 |
| R&D expenditure as a % of operating revenue | 2.87% | 8.64% | 6.52% |
| Operating Revenue | 3,265.36 million | 367.38 million | 285.89 million |
| Net Income | 1,680.33 million | 77.51 million | 63.96 million |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 3,265.36 | 367.38 | 285.89 |
| Operating Costs | 677.78 | 192.85 | 146.75 |
| Operating Income | 1,974.35 | 91.03 | 75.16 |
| Pretax Income | 1,974.28 | 91.30 | 77.00 |
| Income Tax | 293.95 | 13.79 | 13.04 |
| Net Income | 1,680.33 | 77.51 | 63.96 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 3,319.34 | 259.69 | 243.72 |
| Non-current Assets-Total | 253.88 | 101.82 | 93.93 |
| Total Assets | 3,573.22 | 361.51 | 337.65 |
| Liabilities | |||
| Current Liabilities-Total | 1,113.01 | 91.52 | 121.26 |
| Non-current Liabilities-Total | 8.80 | 15.87 | 8.36 |
| Total Liabilities | 1,121.81 | 107.38 | 129.62 |
| Stockholder's Equity | |||
| Share Capital | 669.21 | 118.39 | 118.39 |
| Retained Profits | 1,776.83 | 133.33 | 82.64 |
| Total Owners' Equity | 2,451.41 | 254.13 | 208.03 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 1,790.31 | 54.21 | 44.33 |
| Net Cash Flows-Investing | -548.84 | -11.73 | -18.75 |
| Net Cash Flows-Financing | 503.29 | -60.29 | -5.72 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 安吉福浪莱进出口贸易有限公司 | 23.40 | 19.50% |
| Fangs Holdings Limited Liability Company | 22.50 | 18.75% |
| Shanghai XiangheyongAn Equity Investment Partnership Enterprise (LP) | 12.59 | 10.49% |
| 安吉涌威投资合伙企业（有限合伙） | 12.37 | 10.31% |
| 浙江永石股权投资合伙企业（有限合伙） | 8.27 | 6.90% |
| 上海豪贤实业发展合伙企业（有限合伙） | 2.25 | 1.88% |
| Shanghai Yongchuanghuaxing Investment Partnership Enterprise (LP) | 1.87 | 1.56% |
| Everbright Fortune Investment Co.,Ltd. | 1.38 | 1.15% |
| Lianyungang Yongcheng Equity Investment Partnership Enterprise (LP) | 0.93 | 0.78% |
| 上海永石企业发展合伙企业（有限合伙） | 0.86 | 0.71% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.